Show Search Form

Search Results

registered interest	true false
date	exactly: or between: and
answering body
answering dept id
answering dept short name
answering dept sort name
hansard heading
house id
legislature	pref label
question text
tabling member constituency
tabling member printed
uin
answer	is ministerial correction true false date of answer exactly: or between: and answer text answering member constituency answering member printed grouped question UIN question first answered answering member label previous answer version answering member constituency answering member printed answering member label
tabling member	label

Search

1149333

	registered interest
	date	15/10/2019
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Epilepsy: Drugs
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, whether anti-epileptic drugs are exempted from serious shortage protocols; and what assessment he has made of the potential effect of the use of such protocols on (a) people with learning disabilities and (b) their families in the event that the UK leaves the EU without a withdrawal agreement.
	tabling member constituency	North Norfolk
	tabling member printed	Norman Lamb
	uin	475
	answer	answer is ministerial correction date of answer 21/10/2019 answer text <p>While Serious Shortage Protocols (SSP) in England have the scope to cover all medicines and appliances that are on a National Health Service prescription in primary care, including anti-epileptic drugs, it is clear that an SSP for therapeutic or generic equivalents will not necessarily be suitable for all medicines and patients. For example, where medicines need to be prescribed by brand for clinical reasons, which is the case for epilepsy medication.</p><p>Any protocol would only be introduced if clinicians with expertise in the relevant area think it is appropriate. Pharmacists will have to use their professional judgment as to whether supplying against the protocol rather than the prescription is appropriate or the patient should be referred to their prescriber.</p><p>The legislation enabling Ministers to issue SSPs was not introduced as a European Union exit measure alone but as a business-as-usual measure that can be used before and after our exit from the EU.</p> answering member constituency Charnwood answering member printed Edward Argar question first answered 21/10/2019 13:07:33 answering member 4362 label Biography information for Edward Argar
	tabling member	1439 label Biography information for Norman Lamb

1137560

	registered interest
	date	08/07/2019
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Sexually Transmitted Infections
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, what assessment his Department has made of the correlation between reductions to public health funding and increases in rates of syphilis and gonorrhoea.
	tabling member constituency	North Norfolk
	tabling member printed	Norman Lamb
	uin	274471
	answer	answer is ministerial correction date of answer 11/07/2019 answer text <p>We estimate that increases in rates of syphilis, gonorrhoea and chlamydia are due to a number of factors. These include increases in both the number of people attending sexual health services and the number of tests for sexually transmitted infections. Public Health England has advised that other factors include, better detection of infection and behavioural changes such as an increase in partner numbers and condomless sex, as well as, for some men who have sex with men, ‘chemsex’ and group sex facilitated by geosocial networking applications.</p><p> </p><p>Local authorities will receive £3.1 billion in 2019/20, ring-fenced exclusively for use on public health, including sexual health. We are investing over £16 billion in local authority public health services over the five years of the 2015 Spending Review until 2020/21. It is for individual local authorities to decide their spending priorities based on an assessment of local need, including the need for sexual health services taking account of their statutory duties.</p><p> </p><p>Local authorities are required by regulations to provide comprehensive open access sexual health services, including provision for sexually transmitted infection testing and treatment and contraception.</p><p> </p><p>The latest statistics show that more people are now accessing sexual health services. Attendances have increased by 7% between 2017 and 2018 (from 3,337,677 to 3,561,548). This continues the trend of increases in attendances seen over the past five years. To help manage the overall increase in demand, local authorities are increasingly commissioning online services to manage lower risk and asymptomatic patients. These services have the potential to reach groups not currently engaged with clinic services.</p><p> </p><p> </p><p> </p><p> </p> answering member constituency South Ribble answering member printed Seema Kennedy question first answered 11/07/2019 13:19:43 answering member 4455 label Biography information for Seema Kennedy
	tabling member	1439 label Biography information for Norman Lamb

1387284

	registered interest
	date	13/12/2021
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Evusheld
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, what assessment he has made of the effectiveness of the AstraZeneca drug Evusheld for immunosuppressed people in the UK; what plans he has to use that drug as a (a) prophylactic and (b) treatment; and what his timeline is for the rollout of that drug for use in the UK.
	tabling member constituency	North Norfolk
	tabling member printed	Duncan Baker
	uin	92097
	answer	answer is ministerial correction date of answer 20/12/2021 answer text <p>We continue to monitor the emerging data for AstraZeneca’s long-acting antibody therapy, AZD7442, also known as Evusheld. AstraZeneca have discussed potential approvals with the Medicines and Healthcare products Regulatory Agency .</p><p>The Department published a Prior information Notice (PIN) on 5 October 2021 inviting suppliers to submit an expression of interest on neutralising antibody treatments being developed for treating and preventing COVID-19. The PIN is accessible by suppliers and enables the Department to undertake a fair and transparent market engagement process with suppliers. We are unable to provide further information on the deployment of Evusheld as it is commercially sensitive.</p> answering member constituency Erewash answering member printed Maggie Throup question first answered 20/12/2021 12:14:28 answering member 4447 label Biography information for Maggie Throup previous answer version 39905 answering member constituency Erewash answering member printed Maggie Throup answering member 4447 label Biography information for Maggie Throup
	tabling member	4784 label Biography information for Duncan Baker

1452143

	registered interest
	date	17/03/2022
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Immunosuppression: Evusheld
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, pursuant to the Answer of 20 December 2021 to Question 92097 and following the Conditional Marketing Authorisation awarded by the Medicines and Healthcare products Regulatory Agency on 17 March 2022, what plans he has to ensure that severely immunocompromised patients have access to Evusheld; and what estimate he has made of when the first patients will start to receive that treatment.
	tabling member constituency	North Norfolk
	tabling member printed	Duncan Baker
	uin	142089
	answer	answer is ministerial correction date of answer 24/03/2022 answer text <p>We are unable to provide the information requested as it is commercially sensitive. Any public announcement on the procurement of treatments would be made after an agreement is reached with companies. The Department is scoping the potential introduction of pre-exposure prophylaxis. This includes identification of the most appropriate patient groups which could benefit and the potential deployment and administration process. However, treatments must be clinically cost-effective and demonstrate sufficient efficacy against Omicron and new variants.</p> answering member constituency Erewash answering member printed Maggie Throup question first answered 24/03/2022 16:51:12 answering member 4447 label Biography information for Maggie Throup
	tabling member	4784 label Biography information for Duncan Baker

1339447

	registered interest
	date	23/06/2021
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Coronavirus: Vaccination
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, what assessment he has made of (a) using the existing 2020-21 flu vaccination list for all future covid-19 booster vaccines and (b) the potential merits of using that list to protect all vulnerable people, including those with asthma who take daily Inhaled steroids.
	tabling member constituency	North Norfolk
	tabling member printed	Duncan Baker
	uin	21346
	answer	answer is ministerial correction date of answer 28/06/2021 answer text <p>We are preparing for a potential booster vaccination programme from the autumn. Whilst we are planning for several potential scenarios, final decisions on the timing and scope of the booster programme will not be taken until later this year, in line with results from key clinical studies and independent advice from the Joint Committee for Vaccination and Immunisation (JCVI). The JCVI will review the emerging scientific evidence from studies on co-administering the flu and COVID-19 vaccines safely, alongside data supplied by manufacturers, to inform the Government in the decision-making process.</p> answering member constituency Stratford-on-Avon answering member printed Nadhim Zahawi question first answered 28/06/2021 13:34:09 answering member 4113 label Biography information for Nadhim Zahawi
	tabling member	4784 label Biography information for Duncan Baker

1304267

	registered interest
	date	19/03/2021
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	NHS and Care Workers: Incentives
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, what assessment he has made of the potential merits of a one-off bonus-payment for NHS and social care workers in England; and what discussions he has had with the Chancellor of the Exchequer on the affordability of such a payment.
	tabling member constituency	North Norfolk
	tabling member printed	Duncan Baker
	uin	172118
	answer	answer is ministerial correction date of answer 12/04/2021 answer text <p>We are looking to the independent Pay Review Bodies (PRBs) for a recommendation on NHS pay, who consider a range of factors, including, motivation, morale and affordability. The Department and HM Treasury work together closely during the PRB process.</p><p>As the PRBs are independent of the Government, we cannot pre-judge their recommendations. Once received, we will take time to carefully consider their recommendations before responding.</p><p>The vast majority of care workers are employed by private sector providers who ultimately set their pay and remuneration, independent of central Government. Local authorities work with care providers to determine a fair rate of pay based on local market conditions</p> answering member constituency Faversham and Mid Kent answering member printed Helen Whately question first answered 12/04/2021 11:11:40 answering member 4527 label Biography information for Helen Whately
	tabling member	4784 label Biography information for Duncan Baker

1137564

	registered interest
	date	08/07/2019
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Genito-urinary Medicine and HIV Infection
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, whether the Prevention Green Paper will include (a) commitments on additional resources to tackle HIV and (b) targets to improve sexual health.
	tabling member constituency	North Norfolk
	tabling member printed	Norman Lamb
	uin	274473
	answer	answer is ministerial correction date of answer 11/07/2019 answer text <p>We are considering a range of policy options for the Green Paper and will be mindful of HIV and sexual health.</p> answering member constituency South Ribble answering member printed Seema Kennedy question first answered 11/07/2019 13:32:41 answering member 4455 label Biography information for Seema Kennedy
	tabling member	1439 label Biography information for Norman Lamb

1137563

	registered interest
	date	08/07/2019
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Preventive Medicine: Finance
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, whether the Green Paper on Prevention will include and assessment of the level of funding required to implement the contents of that Green Paper.
	tabling member constituency	North Norfolk
	tabling member printed	Norman Lamb
	uin	274472
	answer	answer is ministerial correction date of answer 11/07/2019 answer text <p>We are considering a number of policy options for the Prevention Green Paper and will be mindful of the level of funding that may be required for their implementation.</p> answering member constituency South Ribble answering member printed Seema Kennedy question first answered 11/07/2019 13:32:12 answering member 4455 label Biography information for Seema Kennedy
	tabling member	1439 label Biography information for Norman Lamb

1272919

	registered interest
	date	30/12/2020
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Vitamin D
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, what scientific evidence informed the recommendation of the level for vitamin D supplementations.
	tabling member constituency	North Norfolk
	tabling member printed	Duncan Baker
	uin	133243
	answer	answer is ministerial correction date of answer 11/01/2021 answer text <p>United Kingdom vitamin D recommendations are based on advice from the Scientific Advisory Committee on Nutrition (SACN). The SACN is an advisory committee of independent experts that advises the Government on nutrition-related matters.</p><p>In its 2016 report on vitamin D and health, the SACN carried out an extensive and robust assessment of the evidence on vitamin D and a wide range of musculoskeletal and non-musculoskeletal health outcomes, including infection. The SACN report is available at the following link:</p><p><a href="https://www.gov.uk/government/publications/sacn-vitamin-d-and-health-report" target="_blank">https://www.gov.uk/government/publications/sacn-vitamin-d-and-health-report</a></p> answering member constituency Bury St Edmunds answering member printed Jo Churchill question first answered 11/01/2021 22:04:34 answering member 4380 label Biography information for Jo Churchill
	tabling member	4784 label Biography information for Duncan Baker

1135827

	registered interest
	date	01/07/2019
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	NHS England: Private Sector
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, what estimate he has made of the total payments made by NHS England to private providers in each of the last five years.
	tabling member constituency	North Norfolk
	tabling member printed	Norman Lamb
	uin	271400
	answer	answer is ministerial correction date of answer 04/07/2019 answer text <p>Total spending by NHS Commissioners on private health providers in each of the last five years for which figures are available is shown in the following table.</p><table><tbody><tr><td><p>NHS Commissioners' spend on non National Health Service bodies by organisation type</p></td><td><p>2013/14</p></td><td><p>2014/15</p></td><td><p>2015/16</p></td><td><p>2016/17</p></td><td><p>2017/18</p></td></tr><tr><td><p> </p></td><td><p>£ million</p></td><td><p>£ million</p></td><td><p>£ million</p></td><td><p>£ million</p></td><td><p>£ million</p></td></tr><tr><td><p>Independent sector providers</p></td><td><p>6,467</p></td><td><p>8,067</p></td><td><p>8,818</p></td><td><p>9,007</p></td><td><p>8,765</p></td></tr></tbody></table><p><br> Note: 1. The numbers above have been collected separately from audited accounts data and may include estimates.</p><p> </p> answering member constituency Wimbledon answering member printed Stephen Hammond question first answered 04/07/2019 11:03:36 answering member 1585 label Biography information for Stephen Hammond
	tabling member	1439 label Biography information for Norman Lamb

1128626

	registered interest
	date	23/05/2019
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Whorlton Hall Hospital
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, what the average weekly fee per patient charged to the NHS was for the provision of care by Cygnet at Whorlton Hall.
	tabling member constituency	North Norfolk
	tabling member printed	Norman Lamb
	uin	257682
	answer	answer is ministerial correction date of answer 05/06/2019 answer text <p>This information is not held centrally.</p> answering member constituency Gosport answering member printed Caroline Dinenage question first answered 05/06/2019 14:03:55 answering member 4008 label Biography information for Dame Caroline Dinenage
	tabling member	1439 label Biography information for Norman Lamb

1307228

	registered interest
	date	12/04/2021
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Coronavirus: Vaccination
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, what assessment he has made of the (a) importance of the OCTAVE trial and the timescale for its preliminary and full results for people who are clinically extremely vulnerable immunosuppressed and (b) level of risk to those people during the period from the end of shielding to the completion of the covid-19 vaccination programme for all adults; and what steps he is taking to reduce the risk of infection and protect people who are immunosuppressed, who may not fully benefit from their own vaccination, in addition to prioritising the vaccination for the people who live with them.
	tabling member constituency	North Norfolk
	tabling member printed	Duncan Baker
	uin	179602
	answer	answer is ministerial correction date of answer 15/04/2021 answer text <p>This OCTAVE study will provide important insights into the effectiveness of COVID-19 vaccines in clinically at-risk groups. This includes COVID-19 vaccine responses in patients with certain immunosuppressed conditions, including those with inflammatory disorders, high risk cancer patient groups, and patients with severe kidney and liver disease. The research will use comprehensive immune tests performed on blood samples taken before and/or after COVID-19 vaccination. It will determine patients’ COVID-19 immune response and therefore the likelihood that vaccines will fully protect these groups from COVID-19 infection. Key sample timings include 28 days and 6 months post vaccine boost. Results will be available within three months of sampling date. It is estimated that initial results for 28 days post-vaccine will be available across the majority of the cohort by the middle of June.</p><p>The decision to pause shielding was based on the epidemiological data which showed that cases of COVID-19 had fallen considerably from when national restrictions were first introduced in January. In addition to the prioritisation for COVID-19 vaccines of households of immunosuppressed individuals, the Government continues to provide all clinically extremely vulnerable individuals with additional guidance that they are advised to take to help protect themselves.</p> answering member constituency Bury St Edmunds answering member printed Jo Churchill question first answered 15/04/2021 16:29:59 answering member 4380 label Biography information for Jo Churchill
	tabling member	4784 label Biography information for Duncan Baker

1128556

	registered interest
	date	23/05/2019
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Influenza: Vaccination
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, when his Department plans to publish data on the uptake of influenza vaccinations by social care workers in 2018-19.
	tabling member constituency	North Norfolk
	tabling member printed	Norman Lamb
	uin	257680
	answer	answer is ministerial correction date of answer 05/06/2019 answer text <p>There is no nationally agreed data set or data collection for recording the immunisation of social care workers.</p> answering member constituency South Ribble answering member printed Seema Kennedy question first answered 05/06/2019 15:16:16 answering member 4455 label Biography information for Seema Kennedy
	tabling member	1439 label Biography information for Norman Lamb

1669489

	registered interest
	date	13/11/2023
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Neurodiversity: Diagnosis
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, how many people were diagnosed with (a) autism, (b) ADHD and (c) dyslexia in the East of England in the last five years.
	tabling member constituency	North Norfolk
	tabling member printed	Duncan Baker
	uin	1733
	answer	answer is ministerial correction date of answer 21/11/2023 answer text <p>The information requested is not held centrally but may be held locally by individual National Health Service trusts or commissioners.</p> answering member constituency Lewes answering member printed Maria Caulfield question first answered 21/11/2023 11:28:22 answering member 4492 label Biography information for Maria Caulfield
	tabling member	4784 label Biography information for Duncan Baker

1315695

	registered interest
	date	18/05/2021
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Coronavirus: Vaccination
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, with reference to the Answer of 26 April 2021 to Question 181447 on Coronavirus: Vaccination, for what reason The National Institute for Health and Care Excellence’s guideline and Bloom et al were not used by the JCVI in determining the vaccination priority list.
	tabling member constituency	North Norfolk
	tabling member printed	Duncan Baker
	uin	3184
	answer	answer is ministerial correction date of answer 24/05/2021 answer text <p>The definitions used by the Joint Committee on Vaccination and Immunisation (JCVI) were based on evidence of the risk from COVID-19 disease as set out by OpenSAFELY and QCOVID.</p><p>The National Institute for Health and Care Excellence guideline on severe asthma was based on European Respiratory Society and American Thoracic Society definitions of severe asthma, which are not related to the risk of hospitalisation associated with COVID-19 disease. Similarly, the Bloom et al definition is not based on COVID-19 disease risk. Therefore, these definitions were not used. The JCVI has advised that all adults should be offered COVID-19 vaccination, unless it is contraindicated.</p> answering member constituency Stratford-on-Avon answering member printed Nadhim Zahawi question first answered 24/05/2021 15:37:49 answering member 4113 label Biography information for Nadhim Zahawi
	tabling member	4784 label Biography information for Duncan Baker

1132981

	registered interest
	date	18/06/2019
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	NHS: Legal Costs
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, pursuant to the Answer of 17 June 2019 to Question 263752 on NHS: Legal Costs, how much was money was spent by (a) NHS England, (b) NHS trusts, (c) Health Education England and (d) NHS Improvement on the services of (a) Bevan Brittan, (b) Mills & Reeve, (c) DAC Beechcroft, (d) Hempsons, (e) Capsticks and (f) Hill Dickinson in relation to employment disputes in each of the last five years.
	tabling member constituency	North Norfolk
	tabling member printed	Norman Lamb
	uin	266123
	answer	answer is ministerial correction date of answer 24/06/2019 answer text <p>The arm’s length bodies concerned do not collect information in the format requested. The transactions charged by the organisations involved do not specifically itemise legal costs as ‘employment disputes’.</p> answering member constituency Gosport answering member printed Caroline Dinenage question first answered 24/06/2019 15:28:59 answering member 4008 label Biography information for Dame Caroline Dinenage
	tabling member	1439 label Biography information for Norman Lamb

1131616

	registered interest
	date	12/06/2019
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	NHS: Legal Costs
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, how much was money was spent by (a) NHS England, (b) NHS Trusts, (c) Health Education England and (d) NHS Improvement on the services of (a) Bevan Brittan, (b) Mills & Reeve, (c) DAC Beechcroft, (d) Hempsons, (e) Capsticks and (f) Hill Dickinson in relation to employment and whistleblower disputes in each of the last five years.
	tabling member constituency	North Norfolk
	tabling member printed	Norman Lamb
	uin	263752
	answer	answer is ministerial correction date of answer 17/06/2019 answer text <p>The arm’s length bodies concerned do not collect information in a way that would enable them to answer this question in the format requested.</p> answering member constituency Gosport answering member printed Caroline Dinenage question first answered 17/06/2019 15:42:04 answering member 4008 label Biography information for Dame Caroline Dinenage
	tabling member	1439 label Biography information for Norman Lamb

1240514

	registered interest
	date	06/10/2020
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Mental Health Services
	house id	1
	legislature	25259 pref label House of Commons
	question text	What steps his Department is taking to increase the number of mental health hubs in the community.
	tabling member constituency	North Norfolk
	tabling member printed	Duncan Baker
	uin	907133
	answer	answer is ministerial correction date of answer 06/10/2020 answer text <p>The NHS Long Term Plan set out a vision for providing integrated mental health support across primary and community services to ensure people can access the care, treatment and support at the earliest point of need.</p><p>All local areas have received funding to develop and deliver these new models of integrated care by 2023-24. The Government has not prescribed the form these should take though they may take the form of community mental health hubs.</p> answering member constituency Mid Bedfordshire answering member printed Ms Nadine Dorries question first answered 06/10/2020 15:57:09 answering member 1481 label Biography information for Ms Nadine Dorries
	tabling member	4784 label Biography information for Duncan Baker

1352544

	registered interest
	date	03/09/2021
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Coronavirus: Vaccination
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, with reference to the findings of (a) the ONS that chronic lower respiratory disease is the third most common underlying condition with death as a result of covid-19 in quarter 2 of 2021 and (b) of the British Lung Foundation, in its 2012 survey, that 81 per cent of chronic lower respiratory disease is asthma, if he will make it his policy that people with asthma who receive a free annual flu vaccination will be included in any covid-19 booster vaccination programme.
	tabling member constituency	North Norfolk
	tabling member printed	Duncan Baker
	uin	42174
	answer	answer is ministerial correction date of answer 08/09/2021 answer text <p>The Joint Committee on Vaccination and Immunisation’s (JCVI) interim advice is that COVID-19 booster vaccinations should first be offered to the most vulnerable. The JCVI advises a two stage approach, with individuals in stage one offered a booster vaccine and flu vaccine, as soon as possible from September. Individuals in stage two would be offered a booster vaccine as soon as practicable after stage one, with equal emphasis on deployment of the flu vaccine where eligible. The JCVI suggests those aged 16 to 49 years old who are in an influenza or COVID-19 at risk group, including some patients with chronic respiratory disease and asthma are currently included in stage two.</p><p>Final decisions on the timing and scope and cohort eligibility, booster programme will be confirmed once the JCVI has provided their final advice.</p> answering member constituency Stratford-on-Avon answering member printed Nadhim Zahawi grouped question UIN 41664 question first answered 08/09/2021 15:14:11 answering member 4113 label Biography information for Nadhim Zahawi
	tabling member	4784 label Biography information for Duncan Baker

1309476

	registered interest
	date	15/04/2021
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Coronavirus: Vaccination
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, with reference to (a) the definition of severe asthma set out in paragraph 1.2 of the NICE 2020 publication, COVID-19 rapid guideline: severe asthma and (b) the article by Bloom et al published in The Lancet on 4 March 2021, what assessment his Department has made of the potential merits of prioritising all asthmatics in (i) phase 2 and (ii) future phases including booster shots of the covid-19 vaccine rollout; and whether the JCVI considered the NICE guidelines on covid-19 and severe asthma when setting out the approach to covid-19 vaccination roll out in the UK.
	tabling member constituency	North Norfolk
	tabling member printed	Duncan Baker
	uin	181447
	answer	answer is ministerial correction date of answer 26/04/2021 answer text <p>The Joint Committee on Vaccination and Immunisation (JCVI) considered data from OpenSAFELY and QCOVID in determining the risk of COVID-19 in those with asthma and in determining which individuals with asthma were at significant risk of mortality from COVID-19 in phase one of the COVID-19 vaccination programme. The JCVI concluded that only a subset of those with asthma are at clinically higher risk from COVID-19. This group is defined by data from OpenSAFELY and QCOVID as adults with asthma who require continuous or repeated use of systemic steroids or with previous exacerbations requiring hospital admission. The National Institute for Health and Care Excellence’s guideline Bloom et al were not used.</p><p>For phase two, the JCVI concluded that there is good evidence that the risks of hospitalisation and critical care admission from COVID-19 increase with age. The JCVI advised that the offer of vaccination during phase two is age-based starting with the oldest adults first. The JCVI has not advised prioritisation of any sub-groups and is currently considering the need for and timing of future phases and booster doses of COVID-19 vaccines. Their advice will be published in due course.</p> answering member constituency Stratford-on-Avon answering member printed Nadhim Zahawi question first answered 26/04/2021 16:06:02 answering member 4113 label Biography information for Nadhim Zahawi previous answer version 98078 answering member constituency Stratford-on-Avon answering member printed Nadhim Zahawi answering member 4113 label Biography information for Nadhim Zahawi
	tabling member	4784 label Biography information for Duncan Baker

1259420

	registered interest
	date	08/12/2020
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Care Homes: Learning Disability
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, what steps his Department has taken to prioritise people in care home settings with learning disabilities for covid-19 vaccination; and if he will take steps to ensure that those people are vaccinated with higher priority than priority level six in the context of the covid-19 mortality rate among adults with learning disabilities.
	tabling member constituency	North Norfolk
	tabling member printed	Duncan Baker
	uin	127009
	answer	answer is ministerial correction date of answer 22/12/2020 answer text <p>The Joint Committee on Vaccination and Immunisation (JCVI) advise the Government on which vaccine(s) the United Kingdom should use and provide advice on prioritisation.</p><p>As the highest risk of mortality increases with age, the JCVI advise that care home residents, their staff and those over 80 years old should be the first group to receive the vaccine. Adults with Down's syndrome and people with a severe and profound learning disability are also prioritised to receive the vaccine; they are within the fourth and sixth vaccine prioritisation groups respectively.</p><p>With regards to prioritising vaccines for people in care home settings with learning disabilities higher than in their current group six category, we will continue to review the evidence and advice from the JCVI as it emerges to determine if this is required.</p> answering member constituency Stratford-on-Avon answering member printed Nadhim Zahawi question first answered 22/12/2020 12:21:23 answering member 4113 label Biography information for Nadhim Zahawi previous answer version 69150 answering member constituency Stratford-on-Avon answering member printed Nadhim Zahawi answering member 4113 label Biography information for Nadhim Zahawi
	tabling member	4784 label Biography information for Duncan Baker

1399405

	registered interest
	date	04/01/2022
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Coronavirus: Protective Clothing
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, for what reason the Government does not recommend (a) FFP2 and (b) FFP3 face masks as offering additional protection to the wearer against covid-19.
	tabling member constituency	North Norfolk
	tabling member printed	Duncan Baker
	uin	97144
	answer	answer is ministerial correction date of answer 02/03/2022 answer text <p>The Health and Safety Executive does not recommend the routine use of FFP2 masks in clinical practice as these are of lower efficacy than FFP3 masks. FFP3 masks are recommended for use in some health and care settings. Infection prevention and control guidance for staff in all health and care settings states that FFP3 masks should be worn by staff caring for patients where a risk assessment indicates the need.</p><p>FFP3 masks and other higher specification personal protective equipment must be professionally fit tested to ensure that air flows through the filter rather than around the mask. If these masks are provided without fit testing, it is not clear that they will be effective. Additionally, it may be difficult for members of the public to safely and comfortably wear a fitted mask for extended periods of time. Face coverings are no longer mandated by law.</p><p><em> </em></p> answering member constituency Erewash answering member printed Maggie Throup question first answered 02/03/2022 09:52:27 answering member 4447 label Biography information for Maggie Throup
	tabling member	4784 label Biography information for Duncan Baker

1166900

	registered interest
	date	28/10/2019
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Health: Children
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, what steps the Government is taking to fulfill its commitment in its Prevention Green Paper to seek views on how to improve the healthy social and emotional development of babies and young children.
	tabling member constituency	North Norfolk
	tabling member printed	Norman Lamb
	uin	6261
	answer	answer is ministerial correction date of answer 05/11/2019 answer text <p>The Government is taking steps to fulfil its commitment in its Prevention Green Paper to seek views on how to improve the healthy social and emotional development of babies and young children.</p><p>Public Health England’s (PHE’s) vision is to improve the health of babies, children and their families and to enable the foundations of good health into adulthood. A large proportion of this work will be done through the modernisation of the Healthy Child Programme, which is PHE’s national offer to our children and families. This can be viewed at the following links:</p><p> </p><p><a href="https://www.gov.uk/government/publications/healthy-child-programme-pregnancy-and-the-first-5-years-of-life" target="_blank">https://www.gov.uk/government/publications/healthy-child-programme-pregnancy-and-the-first-5-years-of-life</a></p><p><a href="https://www.gov.uk/government/publications/healthy-child-programme-5-to-19-years-old" target="_blank">https://www.gov.uk/government/publications/healthy-child-programme-5-to-19-years-old</a></p> answering member constituency Bury St Edmunds answering member printed Jo Churchill question first answered 05/11/2019 12:02:19 answering member 4380 label Biography information for Jo Churchill
	tabling member	1439 label Biography information for Norman Lamb

1138829

	registered interest
	date	15/07/2019
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Mental Health Services
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, what plans his Department has to improve support for people with neurodevelopmental conditions.
	tabling member constituency	North Norfolk
	tabling member printed	Norman Lamb
	uin	277125
	answer	answer is ministerial correction date of answer 18/07/2019 answer text <p>The Government is committed to supporting people with neurodevelopmental conditions to live well. We are currently reviewing the adult autism strategy and working with the Department of Education will be extending the scope of the strategy to include children. The refreshed strategy will be published by the end of the year. We are also working closely with the National Institute for Health and Care Excellence (NICE) and their attention deficit hypersensitivity disorder (ADHD) Implementation Working Group to look at how the current NICE guidance and quality standard on ADHD are being implemented. This work includes looking to identify best practice and examples of innovation, which have improved outcomes for people with ADHD, so that these can be widely disseminated to commissioners to improve local practice. We are considering what actions can be taken to support those with other neurodevelopmental conditions.</p> answering member constituency Gosport answering member printed Caroline Dinenage question first answered 18/07/2019 09:28:06 answering member 4008 label Biography information for Dame Caroline Dinenage
	tabling member	1439 label Biography information for Norman Lamb

1388172

	registered interest
	date	15/12/2021
	answering body	Department of Health and Social Care
	answering dept id	17
	answering dept short name	Health and Social Care
	answering dept sort name	Health and Social Care
	hansard heading	Coronavirus: Vaccination
	house id	1
	legislature	25259 pref label House of Commons
	question text	To ask the Secretary of State for Health and Social Care, pursuant to the Answer of 14 December 2021 to Question 89686 on Coronavirus: Vaccination, when 16-17 year olds with chronic asthma in group 6 will be (a) eligible and (b) prioritised for a covid-19 booster vaccination; and whether he will use the flu jab list as a basis for efficiently identifying those who need to be prioritised for any future covid-19 booster vaccinations.
	tabling member constituency	North Norfolk
	tabling member printed	Duncan Baker
	uin	93909
	answer	answer is ministerial correction date of answer 31/01/2022 answer text <p>The Government accepted advice from the Joint Committee on Vaccination and Immunisation (JCVI) that those aged 16 to 49 years old with underlying health conditions which put them at higher risk of severe COVID-19 should be offered a booster vaccine. This included individuals with 'poorly controlled asthma', defined as:</p><p>- Receiving two or more courses of oral corticosteroids in the preceding 24 months;</p><p>- Being on maintenance oral corticosteroids; and</p><p>- Having one or more hospital admission(s) for asthma in the preceding 24 months.</p><p>The flu clinical risk groups were initially considered as a potential way to identify and prioritise individuals at risk of COVID-19. However, when evaluating the data, the JCVI found that, although there was some overlap between the influenza clinical risk groups and those at high risk of severe COVID-19, there were some differences. At this stage no decision has been made about who will be prioritised for any for any future booster vaccinations, and whether the flu clinical risk groups will be used as part of the considerations.</p> answering member constituency Erewash answering member printed Maggie Throup question first answered 31/01/2022 15:45:21 answering member 4447 label Biography information for Maggie Throup previous answer version 42115 answering member constituency Erewash answering member printed Maggie Throup answering member 4447 label Biography information for Maggie Throup
	tabling member	4784 label Biography information for Duncan Baker